Dr. Alexander Augustyn, MD, PhD

Dr. Augustyn practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Augustyn's NPI, 1265893184, was assigned on March 20, 2016. Dr. Augustyn graduated from UT Southwestern Medical Center in 2016. Dr. Augustyn's Indiana license number on file is 01084669A.

Dr. Augustyn's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Augustyn's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Augustyn is also affiliated with Community Hospital East. The medical group on file is Physicians Referral Service. Dmand AI also links Dr. Augustyn to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Augustyn practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Augustyn's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Augustyn is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Augustyn's licenses on file in 2 states: Indiana and Texas.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, head & neck cancer radiation, lung cancer radiation and lymphoma radiation among the conditions Dr. Augustyn treats.

CMS data shows 2,937 Medicare services from Dr. Augustyn across 20 procedure codes in 2024, for 214 Medicare patients. Medicare paid $181,867 for them. Every service was in an office.

CMS counts 214 Medicare patients who saw Dr. Augustyn in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have cancer, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Augustyn's median patient age at 74, with 56% women.

In 2024, Dr. Augustyn wrote 301 Medicare Part D claims for 92 patients. 99% of them were for generic drugs. CMS names the drug for 210 of them, across 9 drugs with 11 or more claims each, at $3,793 in total drug cost. In 2023, CMS named 95 claims across 5 drugs.

Dr. Augustyn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Augustyn as offering telehealth.

Dmand AI links 30 papers to Dr. Augustyn, published from 2014 to 2023. 2014 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Cell Line, Tumor and Basic Helix-Loop-Helix Transcription Factors. Dr. Augustyn has published most often in Front Oncol. Dr. Augustyn's most frequent co-authors are John Dorrance Minna, MD, Ethan Bernard Ludmir, MD and Stephen G. Chun, MD.

CMS Open Payments shows 3 general payments to Dr. Augustyn from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $76.

Dr. Augustyn graduated from UT Southwestern Medical Center in 2016.

Dr. Augustyn is in network with 13 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.